What is the appropriate acute management for a dyspneic, slightly cyanotic woman with ankle, pretibial, and sacral edema, distended neck veins, an irregular heartbeat with discordant apex (100 beats/min) and radial pulse (70 beats/min) rates, hypotension (blood pressure 100/65 mmHg), loud rumbling diastolic murmur at the apex, enlarged tender liver, ascites, and basal crackles consistent with severe mitral stenosis complicated by atrial fibrillation with rapid ventricular response and decompensated biventricular failure?

Acute Management of Severe Mitral Stenosis with Atrial Fibrillation and Decompensated Biventricular Failure

This patient requires immediate rate control of atrial fibrillation, aggressive diuresis for pulmonary and systemic congestion, anticoagulation with vitamin K antagonist (not NOACs), and urgent evaluation for percutaneous mitral commissurotomy (PMC) or mitral valve surgery once stabilized.

Immediate Stabilization (First Hours)

Rate Control of Atrial Fibrillation

The pulse deficit (apex 100 bpm vs radial 70 bpm) indicates rapid ventricular response with inadequate peripheral perfusion. Control ventricular rate urgently using digoxin 0.125-0.25 mg IV or amiodarone 1. Beta-blockers or rate-limiting calcium channel blockers can be used but exercise caution given hypotension (BP 100/65 mmHg) and signs of low cardiac output 2. Digoxin is particularly useful in this setting as it provides rate control without significant negative inotropic effects 2.

• Do not attempt cardioversion before definitive valve intervention - it will not durably restore sinus rhythm in severe mitral stenosis 2
• The atrial fibrillation is driven by chronic left atrial pressure overload and will recur until the stenosis is relieved

Decongestion

Administer IV loop diuretics aggressively to address the pulmonary edema (basal crackles), peripheral edema (ankle, pretibial, sacral), ascites, and hepatic congestion 2, 3. The patient has clear biventricular failure with systemic and pulmonary venous congestion requiring immediate relief.

Anticoagulation

Initiate therapeutic anticoagulation with IV heparin immediately, transitioning to warfarin (target INR 2-3) 2. This is a Class I indication regardless of CHA2DS2-VASc score because:

• Atrial fibrillation with mitral stenosis carries extremely high thromboembolic risk
• NOACs are contraindicated in moderate-to-severe mitral stenosis - only vitamin K antagonists should be used 2, 4
• Transoesophageal echocardiography (TOE) must be performed to exclude left atrial thrombus before any intervention 2

Diagnostic Evaluation (Within 24-48 Hours)

Echocardiographic Assessment

Obtain comprehensive transthoracic echocardiography to:

• Quantify mitral valve area (likely <1.0 cm² given severe symptoms)
• Assess valve anatomy using scoring systems (echocardiographic score, Cormier score) to determine suitability for PMC 2
• Evaluate for mitral regurgitation severity
• Measure pulmonary artery systolic pressure
• Assess biventricular function and tricuspid regurgitation severity

Perform TOE to exclude left atrial thrombus - this is the most important contraindication to PMC 2. If thrombus is present in the left atrial appendage only, anticoagulate for 1-3 months and repeat TOE; if it persists, surgery is indicated 2.

Definitive Management Strategy

Intervention Decision Algorithm

This symptomatic patient with severe mitral stenosis requires intervention 2. The choice depends on valve anatomy and clinical characteristics:

If Favorable Anatomy (echocardiographic score ≤8, no heavy calcification, minimal mitral regurgitation):

PMC is the Class I indication 2. This should be performed once:

• Rate control achieved
• Adequate diuresis completed
• Left atrial thrombus excluded by TOE
• Patient hemodynamically stable

If Unfavorable Anatomy:

Consider the following unfavorable characteristics 2:

• Clinical: NYHA Class IV (present in this patient), permanent atrial fibrillation, severe pulmonary hypertension
• Anatomical: Echocardiographic score >8, heavy calcification, very small valve area, severe tricuspid regurgitation

PMC may still be considered as initial treatment if only mild-moderate calcification and patient has otherwise favorable clinical characteristics 2. However, mitral valve surgery (likely replacement) is indicated if multiple unfavorable features present 2.

Addressing Tricuspid Regurgitation

The enlarged liver and ascites suggest significant tricuspid regurgitation secondary to pulmonary hypertension. If severe tricuspid regurgitation is confirmed and patient requires mitral valve surgery, concomitant tricuspid valve surgery is indicated 3. Even with moderate secondary tricuspid regurgitation, tricuspid repair should be considered if annular dilatation ≥40 mm 3.

Critical Pitfalls to Avoid

1. Never use NOACs in mitral stenosis - only warfarin is appropriate 2, 4
2. Do not delay anticoagulation - thromboembolic risk is extremely high with atrial fibrillation and mitral stenosis
3. Avoid aggressive rate reduction if patient becomes hypotensive - patients with restrictive physiology may deteriorate with sudden heart rate drops 1
4. Do not attempt cardioversion before valve intervention - it will fail to maintain sinus rhythm 2
5. Exclude left atrial thrombus before PMC - this is an absolute contraindication 2

Post-Stabilization Considerations

Once acute decompensation is controlled, multidisciplinary Heart Team evaluation is essential 5 to determine:

• Optimal timing of intervention (urgent vs. semi-urgent)
• PMC vs. surgery based on comprehensive anatomical and clinical assessment
• Surgical risk assessment
• Need for concomitant procedures (tricuspid repair, left atrial appendage management)

If PMC is successful and atrial fibrillation is of recent onset with only moderately enlarged left atrium, cardioversion should be performed soon after the procedure 2. However, with chronic atrial fibrillation and marked atrial enlargement (likely in this patient), permanent rate control with continued anticoagulation is the realistic expectation 2.